ChromaVision Collaborates With UCLA on Advanced HIV Diagnostic Test.SAN JUAN CAPISTRANO San Juan Capistrano (săn wän kăpĭsträ`nō), city (1990 pop. 26,183), Orange co., S Calif.; inc. 1961. San Juan Capistrano has some manufactures, including aircraft parts, medical apparatus, and boats, but the economy is , Calif.--(BUSINESS WIRE)--Nov. 15, 1999-- ChromaVision Medical Systems Inc. (Nasdaq:CVSN), developer of unique cellular imaging diagnostics and manufacturer of the Automated Cellular Imaging System (ACIS)(TM), Monday announced a collaboration with the University of California, Los Angeles UCLA comprises the College of Letters and Science (the primary undergraduate college), seven professional schools, and five professional Health Science schools. Since 2001, UCLA has enrolled over 33,000 total students, and that number is steadily rising. , School of Medicine to enter into feasibility studies to validate a new ACIS-based test to detect and quantify the total Human Immunodeficiency Virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ) reservoir in the peripheral blood cells of HIV-infected persons. UCLA School of Medicine virologist and recognized expert in HIV, Kathie Grovit-Ferbas, Ph.D., will lead the validation studies. The ACIS viral load test Viral load test A new blood test for monitoring the speed of HIV replication in AIDS patients. The viral load test is based on PCR techniques and supplements the CD4+ cell count tests. , performed using the immunohistochemical (IHC) staining method, may improve detection of HIV and provide more meaningful information for treatment decisions and disease management. A new study performed by researchers at Thomas Jefferson University It began as Jefferson Medical College in 1824. On July 1, 1969 the institution officially became Thomas Jefferson University. The university is made up of three colleges:
Grovit-Ferbas received a Ph.D. from the Department of Infectious Diseases and Microbiology at the University of Pittsburgh and has focused her career largely on HIV. She has authored numerous scientific papers relating to HIV and is a member of the UCLA AIDS Institute, directed by Irvin S.Y. Chen, Ph.D. Referring to the current UCLA collaboration with ChromaVision, Grovit-Ferbas said: "The detection of total viral reservoir at the cellular level may prove to be extremely valuable in HIV disease management. In addition, the ACIS could be a very useful tool in ongoing research aimed at developing more effective therapies for this disease." ChromaVision CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and President Dr. Douglas S. Harrington stated: "As with all infectious diseases, it is critical to detect HIV reservoirs with the most sensitive and accurate means possible. Using currently available IHC staining methods, ACIS has the potential to allow the pathologist or laboratory technician to quantify accurately the number of virus infected cells, providing important information to both the doctor and patient." "In parallel with the HIV study, UCLA will be evaluating the use of the ACIS in a related infection that occurs in patients with suppressed or deficient immune systems known as Cytomegalovirus (CMV)," continued Harrington. "CMV is an aggressive virus that affects such immunocompromised individuals as transplant recipients and AIDS patients. This virus often causes blindness or death, and is difficult to detect using conventional means." About ChromaVision Medical Systems ChromaVision Medical Systems manufactures and markets an advanced cellular imaging system designed to advance the detection, diagnosis and treatment of cellular disease. The Automated Cellular Imaging System (ACIS)(TM) combines proprietary, color-based imaging technology with automated microscopy to bring unprecedented sensitivity, accuracy and reproducibility to cancer, infectious disease and genetic cell-based diagnostics. ChromaVision currently markets its products to physicians and researchers in university medical centers and commercial laboratories throughout the world. ChromaVision Medical Systems Inc. (Nasdaq:CVSN) was formed by XL Vision Inc., and is a Safeguard Scientifics Inc. (NYSE NYSE See: New York Stock Exchange :SFE See Sydney Futures Exchange. ) partnership company. For more information on ChromaVision Medical Systems, visit the company's Web site at http://www.chromavision.com. The statements contained herein regarding ChromaVision Medical Systems Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainty of success in developing any new diagnostic test, failure to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance or approval for particular applications and dependence on third parties for clinical testing. ACIS is a trademark of ChromaVision Medical Systems Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion